Invasive pneumococcal disease and consolidated pneumonia in infants: One year of surveillance in three Chilean health care centers;Infección neumocóccica invasora y neumonía consolidante en lactantes: Un año de vigilancia en tres centros hospitalarios chilenos

Revista Chilena de Infectologia

Volumn 25, Issue 2, 2008, Pages 97-103

  Katia Abarca, Villaseca ^a   Rodrigo Vergara, F ^b   Enzo Tassara, P ^c   Isabel Ibanez W ^a   Cristian Garcia B ^a   Marcela Potin, S ^d  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b UNIVERSIDAD DE VALPARAÍSO   (Chile)

^c Servicio de Cirugía Hospital Herminda Martin   (Chile)

^d Glaxo SmithKline Biologicals   (Chile)

Author keywords

Bacteremia; Bacterial vaccines; Epidemiology; Invasive pneumococcal disease; Pneumonia; Streptococcus pneumoniae

Indexed keywords

ANTIINFECTIVE AGENT;

ARTICLE; CHILE; CLASSIFICATION; CLINICAL TRIAL; DRUG EFFECT; FEMALE; HEALTH SURVEY; HUMAN; INFANT; ISOLATION AND PURIFICATION; LOBAR PNEUMONIA; MALE; METHODOLOGY; MULTICENTER STUDY; PRESCHOOL CHILD; PROSPECTIVE STUDY; SEROTYPING; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; CHILD, PRESCHOOL; CHILE; FEMALE; HUMANS; INFANT; MALE; PNEUMOCOCCAL INFECTIONS; PNEUMONIA, PNEUMOCOCCAL; POPULATION SURVEILLANCE; PROSPECTIVE STUDIES; SEROTYPING; STREPTOCOCCUS PNEUMONIAE;

EID: 45349103329     PISSN: 07161018     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Juven T, Mertsola J, Waris M, Leinonen M, Meurman O, Roivainen M, et al. Etiology of community-acquired pneumonia in 254 hospitalized children. Pediatr Infect Dis J 2000; 19: 293-8.
2. Heiskanen-Kosma T, Korppi M, Jokinen C, Kurki S, Heiskanen L, Juvonen H, et al. Etiology of childhood pneumonia: results of a prospective, population based study. Pediatr Infect Dis J 1998; 17: 986-91.
3. rd Edition 2002; Chapter 9: 1-14.
4. El Vigía. Boletín de Vigilancia Epidemiológica de Chile, 1999 (2); 6: 6. Disponible en: epi.minsal.cl/epi/html/elvigia/vigia6.pdf [accedido 20 de septiembre, 2006].
5. Levine M M, Lagos R, Levine O S, Heitmann I, Enríquez N, Pinto M E, et al. Epidemiology of invasive pneumococcal infections in infants and young children in Metropolitan Santiago, Chile, a newly industrializing country. Pediatr Infect Dis J 1998; 17: 287-93.
6. Lagos R, Muñoz A, Valenzuela M, Heitman I, Levine M M. Population-based surveillance for hospitalized and ambulatory pediatric invasive pneumococcal disease in Santiago, Chile. Pediatr Infect Dis J 2002; 21: 1115-23.
7. Diez-Domingo J, Pereiro I, Morant A, Gimeno C, Lerma M, Oyagüez I, et al. Epidemiology of invasive Streptococcus pneumoniae infections in children in Spain, 1996-1998. J Infection 2002; 45: 139-43.
8. Bjorson G L, Sceifele D W, Halperin S A and the Members of the Canadian Paediatric Society/Health Canada Immunization Monitoring Program, Active (IMPACT). Population-based epidemiology of invasive pneumococcal infection in children in nine urban centres in Canada, 1994 through 1998. Pediatr Infect Dis J 2002; 21: 947-50.
9. Rudan I, Tomaskovic L, Boschi-Pinto C, Campbell H, WHO Child Health Epidemiology Reference Group. Global estimate of the incidence of clinical pneumonia among children under five years of age. Bull World Health Org 2004; 82: 895-903.
10. Kaplan S L, Mason E O, Wald E R, Tan T Q, Schutze G E, Bradley J S, et al. Six year multicenter surveillance of invasive pneumococcal infections in children. Pediatr Infect Dis J 2002; 21: 141-7.
11. Centers For Disease Control and Prevention 2001 a 2004. Active Bacterial Core Surveillance (ABCs) Report. Emerging Infections Program Network, Streptococcus pneumoniae, 2004. Disponible en: www.cdc.gov/ncidod/dbmd/ abcs/survreports/spneu04.pdf [accedido: 26 de octubre, 2006]
12. Cartwright K. Pneumococcal disease in Western Europe: burden of disease, antibiotic resistance and management. Eur J Pediatr 2002; 161: 188-95.
13. Heitmann I. Nota breve: Epidemiología nacional de las infecciones causadas por Streptococcus pneumoniae. Rev Chil Infect 1999; 16: 133-6.
14. Lagos R, San Martín O, Erazo L, Avendaño A, Levine MM y Grupo de Trabajo Colaborativo para el Diagnóstico de Infecciones Pneumocóccicas en el Niño. Epidemiología de las enfermedades invasoras causadas por Streptococcus pneumoniae en niños chilenos: Proyecciones clínicas y de salud pública. Rev Chil Infect 2001; 18: 15-21.
15. González P. Vigilancia de la resistencia a antimicrobianos. Rev Chil Infect 2002; 19 Supl 2: 135-9.
16. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen J R, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000; 19: 187-95.
17. Shinefield H R, Black S E. Efficacy of pneumococcal conjugate vaccines in large-scale field trials. Pediatr Infect Dis J 2000; 19: 394-7.
18. Black S E, Shinefield H R, Hansen J, Elvin L, Laufer D, Malinoski F. Post licensure evaluation of effectiveness of seven-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2001; 20: 1105-7.
19. Whitney C G, Farley M M, Hadler J, Harrison L H, Bennett N M, Lynfield R, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348: 1737-46.
20. Ray G T, Whitney C G, Fireman B H, Ciuryla V, Black S B. Cost-effectiveness of pneumococcal conjugated vaccine. Evidence from the 5 years of use in the US incorporating herd effects. Pediatr Infect Dis J 2006; 25: 494-501.
21. Hammitt L L, Bruden D L, Butler J C, Baggett H C, Hurlburt D A, Reasonover A, et al. Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: An explanation of trends in invasive pneumococcal disease. J Infect Dis 2006; 193: 1487-94.
22. Lucero M G, Dulalia V E, Parreno R N, Lim-Quianzon D M, Nohynek H, Makela H, et al. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and pneumonia with consolidation on X-ray in children under two years of age. Cochrane Database of Systematic Reviews 2004, Issue 4. Art. No.: CD004977. DOI: 10.1002/14651858. CD004977.
23. Kyaw M H, Lynfield R, Schaffner W, Craig A S, Hadler J, Reingold A. Effect of introduction of the pneumococcal conjugate vaccine on drug- resistant Streptococcus pneumoniae. N Engl J Med 2006; 354: 1455-63.
24. Grijalva C G, Nuorti J P, Arbogast P G, Martin S W, Edwards K M, Griffin M R. Decline in pneumonia admissions after routine childhood immunization with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 2007; 369: 1179-86.
25. Pelton S I, Huot H M A, Finkelstein J A, Bishop C J, Hsu K K, Kellenberg J, et al. Emergence of 19A as virulent and multidrug resistant pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr Infect Dis J 2007; 26: 468-72
26. Hausdorff W P, Siber G, Paradiso P R. Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children. Lancet 2001; 357: 950-2.
27. Brook I. Unexplained fever in young children: how to manage severe bacterial infection. Br Med J 2003; 327: 1094-7.
28. Asociación Médica Mundial. Principios éticos para las investigaciones médicas en seres humanos. Disponible en: http://www.uchile.cl/bioetica/doc/helsinkrev.htm. [accedido: 20 de septiembre, 2006].
29. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. Good Clinical Practice: Consolidated Guideline. World Health Organization Pneumonia Vaccine Trial Investigators Group. Disponible en: http://www.fda.gov/cder/guidance/959fnl.pdf [accedido: 20 de septiembre, 2006].
30. Ministerio de Salud, República de Chile. Reglamento de los Servicios de Salud, Decreto 140 de 2004, Capítulo V, Título IV, Artículo 44.
31. Memoria Anales Servicio de Salud Valparaíso San Antonio, 1996-2002 http://www.ssvsa.cl/memoria.htm); [accedido: 13 de diciembre, 2007].
32. Murray P R, Rosenthal K S, Kobayashi G S, Pfaller M A. Streptococcus. In: Murray P R, Rosenthal K S, Kobayashi G S, Pfaller M A, editors. Medical Microbiology. St Louis: Mosby Inc; 2002. p 234.
33. Austrian R. The quellung reaction, a neglected microbiologic technique. Mt Sinai J Med 1976; 43: 1053-9.
34. Lee G M, Harper M B. Risk of bacteremia for febrile young children in the post-Haemophilus influenzae type b era. Arch Pediatr Adolesc Med 1998; 152: 624-8.
35. Tregnaghi M, Ceballos A, Ruttimann R, Ussher J, Tregnaghi P, Peeters P, et al. Active epidemiologic surveillance of pneumonia and invasive pneumococcal disease in ambulatory and hospitalized infants in Cordoba, Argentina. Pediatr Infect Dis J 2006; 25: 370-2.
36. Dowell S F, Whitney C G, Wright C, Rose C E Jr, Schuchat A. Seasonal patterns of invasive pneumococcal disease. Emerg Infect Dis 2003; 5: 573-9.
37. Levine O S, Liu G, Garman R L, Dowell S F, Yu S, Yang Y. Haemophilus influenzae type b and Streptococcus pneumoniae as causes of pneumonia among children in Beijing, China. Emerg Infect Dis 2000; 6: 165-70.
38. Bavestrello F, Cabello A, Casanova D. Impacto de medidas regulatorias en la tendencia de consumo comunitario de antibióticos en Chile. Rev Méd Chile 2002; 130: 1265-72.
39. Eskola J, Takala A K, Kilpi TM, Lankinen K S, Kayhty H. Clinical evaluation of new pneumococcal vaccines: the Finnish approach. Dev Biol Stand 1998; 95: 85-92.
40. Black S, Shinefield H, Baxter R, Austrian R, Bracken L, Hansen J, et al. Post licensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente. Pediatr Infect Dis J 2004; 23: 485-9.